PeptideWikipedia The community reference

Talk:Tirzepatide / Archive 1

Archived discussion·1 closed thread

This is an archive of past discussion on Tirzepatide. Do not edit it. To revive a question, open a new section on the current talk page and link back to the thread here.

SURPASS-2 comparator doseResolved

The head-to-head comparison is against semaglutide 1 mg, which is the diabetes dose, not the 2.4 mg obesity dose. Nearly every secondary source that cites this trial omits that, and the omission changes what the result means. — TirzTaxonomist (talk) 10:15, 19 February 2026 (UTC)

Stated explicitly in the evidence section now, with the observation that the distinction is routinely lost. Worth keeping prominent. — TrialsTabitha (talk) 13:42, 19 February 2026 (UTC)

Good. That single sentence prevents a great deal of downstream misreading. ✓ Done — TirzTaxonomist (talk) 09:08, 20 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.